Literature DB >> 1672813

Undifferentiated carcinoma of the ovary.

E G Silva1, C Tornos, M A Bailey, M Morris.   

Abstract

Thirty-five cases of ovarian carcinomas, which had as the predominant histologic component solid areas of epithelial cells without differentiation into müllerian carcinomas, were reviewed. The patients' ages ranged from 39 to 72 years (mean age, 54 years). Two patients had clinical stage I disease, one had stage II, 26 had stage III, and six had stage IV. Microscopically, the malignant cells formed large groups or sheets with desmoplastic stroma around them. Foci of papillary serous carcinoma, unclassified adenocarcinoma, or transitional cell carcinoma were seen in 26 tumors, foci of necrosis were seen in 30 tumors, and vascular invasion was seen in seven tumors. Six of 13 carcinomas tested expressed CA125 reactivity, and 12 of 13 carcinomas reacted to B72.3 monoclonal antibody. The primary tumors were treated by aggressive surgical reduction in 32 patients and by multiple biopsy procedures in three patients. After the first operation, 30 patients had residual disease, smaller than 2 cm in five patients and larger than 2 cm in 23 patients. After surgery, 33 patients received chemotherapy; three of these 33 also received radiotherapy. One patient was treated with postsurgical radiotherapy only, and one patient refused further treatment. Thirty-four patients (97%) died of disease between 8 and 108 months (mean, 27 months) after initial surgery, 29 patients died in less than 32 months. Four patients (11%) survived more than 5 years: two patients with stage I disease who died at 82 and 102 months, one patient with stage II who died at 72 months, and one patient with stage III who has no evidence of disease after 116 months. Five-year survival of patients with undifferentiated ovarian carcinoma is worse than the reported survival of patients with serous carcinoma or ovarian carcinoma with a pattern resembling transitional cell carcinoma. The distinction between these three carcinomas that have solid areas carries prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672813

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.

Authors:  Justyna Mikuła-Pietrasik; Paweł Uruski; Sebastian Szubert; Rafał Moszyński; Dariusz Szpurek; Stefan Sajdak; Andrzej Tykarski; Krzysztof Książek
Journal:  Med Oncol       Date:  2016-07-18       Impact factor: 3.064

Review 2.  The functional multipotency of transforming growth factor β signaling at the intersection of senescence and cancer.

Authors:  Justyna Mikuła-Pietrasik; Szymon Rutecki; Krzysztof Książek
Journal:  Cell Mol Life Sci       Date:  2022-03-19       Impact factor: 9.261

3.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  [Ovarian carcinoma. Do the subtypes reflect different diseases?].

Authors:  M Köbel
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

5.  Ovarian undifferentiated carcinoma with voluminous mesenteric presentation.

Authors:  Rosa Angélica Salcedo-Hernández; Leonardo Saúl Lino-Silva; David Cantú de León; María Delia Pérez-Montiel; Kuauhyama Luna-Ortiz
Journal:  Int J Surg Case Rep       Date:  2012-07-24

Review 6.  Pleomorphic carcinoma of breast: a case report and review of literature.

Authors:  Hongping Tang; Fang Liu; Huang Li; Xinyi Huang; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

7.  Notch1 phenotype and clinical stage progression in non-small cell lung cancer.

Authors:  Dat Nguyen; Larry Rubinstein; Naoko Takebe; Lucio Miele; Joseph E Tomaszewski; Percy Ivy; James H Doroshow; Sherry X Yang
Journal:  J Hematol Oncol       Date:  2015-02-06       Impact factor: 17.388

8.  The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors.

Authors:  Justyna Mikuła-Pietrasik; Paweł Uruski; Sebastian Szubert; Konstantin Maksin; Rafał Moszyński; Dariusz Szpurek; Aldona Woźniak; Stefan Sajdak; Andrzej Tykarski; Krzysztof Książek
Journal:  Biomed Res Int       Date:  2017-09-20       Impact factor: 3.411

9.  Extremely rare case of successful treatment of metastatic ovarian undifferentiated carcinoma with high-dose combination cytotoxic chemotherapy: A case report.

Authors:  Hong Beum Kim; Hee Jeong Lee; Ran Hong; Sang-Gon Park
Journal:  World J Clin Cases       Date:  2020-10-06       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.